← All Enovis CORP filings

Enovis CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
ENOV
Enovis CORP
10-K: Enovis Reports Deep Net Loss Amidst Major Goodwill Impairment
Enovis Corporation posted a significant net loss of $1.18 billion in 2025, primarily driven by substantial goodwill impairment charges, despite a 6.7% increase in net sales.
NYSE
ENOV
Enovis CORP
10-K: Enovis Corporation Reports FY2024 Results, Including Goodwill Impairment Charge
Enovis Corporation's 10-K filing reveals a year marked by strategic acquisitions and a significant goodwill impairment charge, impacting overall financial performance.
NYSE
ENOV
Enovis CORP
10-K: Enovis Corporation 2023 Annual Report: Focus on Medical Technology Growth
Enovis Corporation's 2023 annual report highlights its focus on medical technology, with growth in both Prevention & Recovery and Reconstructive segments, and strategic acquisitions.